Comparar métodos
Revisa los métodos seleccionados uno junto a otro; las filas que difieren aparecen resaltadas.
| UCLA Prostate Cancer Index× | QLQ-LC13 de la EORTC: Calidad de Vida en Cáncer de Pulmón× | |
|---|---|---|
| Campo | Oncología | Oncología |
| Familia | Process / pipeline | Process / pipeline |
| Año de origen≠ | 1998 | 1994 |
| Autor original≠ | Litwin, M. S., et al. | Bergman, B., et al. (EORTC Quality of Life Group) |
| Tipo | Self-report questionnaire | Self-report questionnaire |
| Fuente seminal≠ | Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI ↗ | Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI ↗ |
| Alias≠ | UCLA PCI, PCI | QLQ-LC13 |
| Relacionados | 5 | 5 |
| Resumen≠ | The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes. | The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials. |
| ScholarGateConjunto de datos ↗ |
|
|